Malcolm S Duthie

Summary

Affiliation: Infectious Disease Research Institute
Country: USA

Publications

  1. pmc Protection against Mycobacterium leprae Infection by the ID83/GLA-SE and ID93/GLA-SE Vaccines Developed for Tuberculosis
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, Washington, USA
    Infect Immun 82:3979-85. 2014
  2. ncbi request reprint A rapid ELISA for the diagnosis of MB leprosy based on complementary detection of antibodies against a novel protein-glycolipid conjugate
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA 98102, USA Electronic address
    Diagn Microbiol Infect Dis 79:233-9. 2014
  3. pmc Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment
    M S Duthie
    Infectious Disease Research Institute, 1616 Eastlake Ave East, Suite 400, Seattle, WA, 98102, USA
    Eur J Clin Microbiol Infect Dis 33:639-49. 2014
  4. pmc High levels of soluble CD40 ligand and matrix metalloproteinase-9 in serum are associated with favorable clinical evolution in human visceral leishmaniasis
    Fabrícia Alvisi de Oliveira
    Molecular Biology Laboratory, Hospital Universitário Universidade Federal de Sergipe, Rua Cláudio Batista s n, Bairro Sanatório, Aracaju, Sergipe 49060 10, Brazil
    BMC Infect Dis 13:331. 2013
  5. ncbi request reprint The potential for vaccination in leprosy elimination: new tools for targeted interventions
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA, USA
    Mem Inst Oswaldo Cruz 107:190-6. 2012
  6. doi request reprint Development and pre-clinical assessment of a 73 kD chimeric fusion protein as a defined sub-unit vaccine for leprosy
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Vaccine 31:813-9. 2013
  7. pmc Advances and hurdles on the way toward a leprosy vaccine
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA USA
    Hum Vaccin 7:1172-83. 2011
  8. pmc The development and clinical evaluation of second-generation leishmaniasis vaccines
    Malcolm S Duthie
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Vaccine 30:134-41. 2012
  9. pmc Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development
    Lucas H Sampaio
    Tropical Pathology and Public Health Institute, Federal University of Goias, Goiania, GO 74605050, Brazil
    BMC Infect Dis 11:26. 2011
  10. pmc Antigen-specific cellular and humoral responses are induced by intradermal Mycobacterium leprae infection of the mouse ear
    Malcolm S Duthie
    Infectious Disease Research Institute, Suite 400, 1124 Columbia St, Seattle, WA 98104, USA
    Infect Immun 75:5290-7. 2007

Collaborators

Detail Information

Publications40

  1. pmc Protection against Mycobacterium leprae Infection by the ID83/GLA-SE and ID93/GLA-SE Vaccines Developed for Tuberculosis
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, Washington, USA
    Infect Immun 82:3979-85. 2014
    ..leprae infection. Our data suggest these vaccines could potentially be used as an additional control measure for leprosy. ..
  2. ncbi request reprint A rapid ELISA for the diagnosis of MB leprosy based on complementary detection of antibodies against a novel protein-glycolipid conjugate
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA 98102, USA Electronic address
    Diagn Microbiol Infect Dis 79:233-9. 2014
    ..Due to the speed and robustness of this assay, we believe this is an excellent tool for detecting MB leprosy patients in a simple and highly-quantitative manner. ..
  3. pmc Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment
    M S Duthie
    Infectious Disease Research Institute, 1616 Eastlake Ave East, Suite 400, Seattle, WA, 98102, USA
    Eur J Clin Microbiol Infect Dis 33:639-49. 2014
    ..The consolidation of these results provides a 'response to treatment' signature that could be used within efficacy trials to rapidly and simply determine successful interruption of VL. ..
  4. pmc High levels of soluble CD40 ligand and matrix metalloproteinase-9 in serum are associated with favorable clinical evolution in human visceral leishmaniasis
    Fabrícia Alvisi de Oliveira
    Molecular Biology Laboratory, Hospital Universitário Universidade Federal de Sergipe, Rua Cláudio Batista s n, Bairro Sanatório, Aracaju, Sergipe 49060 10, Brazil
    BMC Infect Dis 13:331. 2013
    ..In this prospective study, we describe the sera kinetics of these two molecules in the course of treatment follow up in human visceral leishmaniasis (VL)...
  5. ncbi request reprint The potential for vaccination in leprosy elimination: new tools for targeted interventions
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA, USA
    Mem Inst Oswaldo Cruz 107:190-6. 2012
    ....
  6. doi request reprint Development and pre-clinical assessment of a 73 kD chimeric fusion protein as a defined sub-unit vaccine for leprosy
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Vaccine 31:813-9. 2013
    ..leprae-induced inflammation in mice. We are using these data to develop new vaccine initiatives for the continued and long-term control of leprosy...
  7. pmc Advances and hurdles on the way toward a leprosy vaccine
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA USA
    Hum Vaccin 7:1172-83. 2011
    ..We summarize and discuss leprosy vaccine strategies that have been deployed previously and discuss those strategies that are currently being developed to augment recent breakthroughs in leprosy control...
  8. pmc The development and clinical evaluation of second-generation leishmaniasis vaccines
    Malcolm S Duthie
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Vaccine 30:134-41. 2012
    ..Finally, potential refinements and surrogate markers that could expedite the introduction of a vaccine that can limit the severity and incidence of leishmaniasis are discussed...
  9. pmc Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development
    Lucas H Sampaio
    Tropical Pathology and Public Health Institute, Federal University of Goias, Goiania, GO 74605050, Brazil
    BMC Infect Dis 11:26. 2011
    ..Until recently, relatively little has been known about the immune responses to individual proteins of M. leprae recognized during leprosy...
  10. pmc Antigen-specific cellular and humoral responses are induced by intradermal Mycobacterium leprae infection of the mouse ear
    Malcolm S Duthie
    Infectious Disease Research Institute, Suite 400, 1124 Columbia St, Seattle, WA 98104, USA
    Infect Immun 75:5290-7. 2007
    ..These results indicate the utility of intradermal ear infection for both induction and understanding of the immune response during M. leprae infection and the identification or testing of new leprosy treatments...
  11. pmc Insight toward early diagnosis of leprosy through analysis of the developing antibody responses of Mycobacterium leprae-infected armadillos
    Malcolm S Duthie
    Infectious Disease Research Institute, 1124 Columbia St, Seattle, WA 98104, USA
    Clin Vaccine Immunol 18:254-9. 2011
    ..leprae infection but also indicate considerable variability in the development of antigen-specific antibodies. Our data suggest that a combination of antigens is likely required to provide accurate and early leprosy diagnosis...
  12. doi request reprint Specific IgG antibody responses may be used to monitor leprosy treatment efficacy and as recurrence prognostic markers
    M S Duthie
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Eur J Clin Microbiol Infect Dis 30:1257-65. 2011
    ..Our data indicate that these responses could be employed as an auxiliary tool for the assessment of treatment efficacy and disease relapse...
  13. ncbi request reprint Treatment with alpha-galactosylceramide before Trypanosoma cruzi infection provides protection or induces failure to thrive
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 168:5778-85. 2002
    ..cruzi infection glycolipids can be used to manipulate iNKT cell responses and suggest the possibility of developing glycolipid treatments that can increase protection and possibly decrease the chronic inflammatory pathology...
  14. pmc Antigen-specific T-cell responses of leprosy patients
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Clin Vaccine Immunol 15:1659-65. 2008
    ..Our results indicate several potential candidate antigens which may be useful for either leprosy diagnosis or vaccination and demonstrate the utility of leprosy WBA that can be applied broadly in clinical or field settings...
  15. pmc Selection of antigens and development of prototype tests for point-of-care leprosy diagnosis
    Malcolm S Duthie
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Clin Vaccine Immunol 15:1590-7. 2008
    ..A serological diagnostic test capable of identifying and allowing treatment of leprosy could reduce transmission, prevent functional disabilities and stigmatizing deformities, and facilitate leprosy eradication...
  16. pmc Use of protein antigens for early serological diagnosis of leprosy
    Malcolm S Duthie
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Clin Vaccine Immunol 14:1400-8. 2007
    ..A serological diagnostic test capable of identifying and allowing treatment of early-stage leprosy could reduce transmission, prevent functional disabilities and stigmatizing deformities, and facilitate leprosy eradication...
  17. pmc Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection
    Vanitha S Raman
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, Washington 98104, USA
    Infect Immun 77:5623-30. 2009
    ....
  18. pmc MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant
    Mark T Orr
    Infectious Disease Research Institute, Seattle, WA, USA
    Eur J Immunol 43:2398-408. 2013
    ..Thus engagement of both the MyD88 and TRIF signaling pathways are essential for the effective adjuvant activity of this TLR4 agonist...
  19. pmc Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant
    Rhea N Coler
    Preclinical Biology, Infectious Disease Research Institute, Seattle, Washington, United States of America
    PLoS ONE 6:e16333. 2011
    ....
  20. pmc Both CD1d antigen presentation and interleukin-12 are required to activate natural killer T cells during Trypanosoma cruzi infection
    Malcolm S Duthie
    Infectious Disease Research Institute, 1124 Columbia St, Suite 600, Seattle, WA 98104, USA
    Infect Immun 73:1890-4. 2005
    ..The required IL-12 arises independently of MyD88. The data support a model of normal NKT-cell activation that requires IL-12 and TCR stimulation...
  21. pmc Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activity
    H W Millie Fung
    IDRI, 1616 Eastlake Ave E, Ste 400, Seattle, WA 98102, USA
    J Nanobiotechnology 11:43. 2013
    ..This nanosuspension is a clinical vaccine adjuvant known as GLA-AF. We examined the effects of DPPC supplier, buffer composition, and manufacturing process on GLA-AF physicochemical and biological activity characteristics...
  22. ncbi request reprint NK cell activation and protection occur independently of natural killer T cells during Trypanosoma cruzi infection
    Malcolm S Duthie
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 600, Seattle, WA 98104, USA
    Int Immunol 17:607-13. 2005
    ..The data presented here argue that during infections NK cell activation and protection occur independently of NKT cells...
  23. doi request reprint Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion
    Susan L Baldwin
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, United States
    Vaccine 27:5956-63. 2009
    ....
  24. pmc Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, Washington 98104, USA
    AAPS PharmSciTech 13:498-506. 2012
    ....
  25. pmc Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis
    Vanitha S Raman
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 185:1701-10. 2010
    ..Our data help to define a correlate of protection during active infection and indicate TLR synergy to be a potentially valuable tool in treating intracellular infections...
  26. doi request reprint Development of a high density hemagglutinin protein microarray to determine the breadth of influenza antibody responses
    Anthony L Desbien
    Infectious Disease Research Institute, Seattle, WA
    Biotechniques 54:345-8. 2013
    ..We are advancing this technology as a platform for rapid, simple, high-throughput assessment of homologous and heterologous antibody responses to influenza disease and vaccination...
  27. pmc During acute Trypanosoma cruzi infection highly susceptible mice deficient in natural killer cells are protected by a single alpha-galactosylceramide treatment
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Immunology 119:355-61. 2006
    ..cruzi required multiple cellular responses, but not the response of NK cells. These results provide useful information because alpha-GalCer is being developed as therapy for infections, autoimmune diseases, allergy and cancers...
  28. pmc Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate
    Hillarie Plessner Windish
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Vaccine 29:7842-8. 2011
    ..ID87/GLA-SE appears to be a promising new vaccine candidate that warrants further development...
  29. pmc Rapid quantitative serological test for detection of infection with Mycobacterium leprae, the causative agent of leprosy
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, Washington, USA
    J Clin Microbiol 52:613-9. 2014
    ..Taken together, these data indicate that the NDO-LID/Smart Reader system can assist in the diagnosis and monitoring of MB leprosy and can detect a significant number of earlier-stage infections. ..
  30. ncbi request reprint Trypanosoma cruzi-infected individuals demonstrate varied antibody responses to a panel of trans-sialidase proteins encoded by SA85-1 genes
    Malcolm S Duthie
    Infectious Disease Research Institute, 1124 Columbia St, Suite 600, Seattle, WA 98104, USA
    Acta Trop 93:317-29. 2005
    ..Together these data indicate that during T. cruzi infection individuals develop a diverse trans-sialidase antibody response that appears to be affected by genetic and environmental factors...
  31. pmc Parasite-induced chronic inflammation is not exacerbated by immunotherapy before or during Trypanosoma cruzi Infection
    Malcolm S Duthie
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Clin Vaccine Immunol 14:1005-12. 2007
    ..cruzi infection, boosts the anti-T. cruzi immune response without exacerbating acute or chronic tissue inflammation. These results argue that prophylactic and therapeutic immunotherapy for Chagas' disease can be developed safely...
  32. pmc A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7
    Christopher B Fox
    Infectious Disease Research Institute IDRI, Seattle, WA, USA
    J Nanobiotechnology 12:17. 2014
    ..Ligands of each of these TLRs generally have disparate biochemical properties, however, and straightforward co-formulation may represent an obstacle...
  33. pmc Rational design and evaluation of a multiepitope chimeric fusion protein with the potential for leprosy diagnosis
    Malcolm S Duthie
    Protein Advances Inc, 1102 Columbia St, Seattle, WA 98104, USA
    Clin Vaccine Immunol 17:298-303. 2010
    ....
  34. pmc Critical proinflammatory and anti-inflammatory functions of different subsets of CD1d-restricted natural killer T cells during Trypanosoma cruzi infection
    Malcolm S Duthie
    IDRI, 1124 Columbia St, Ste 600, Seattle, WA 98104, USA
    Infect Immun 73:181-92. 2005
    ..Strikingly, most Jalpha18(-/-) mice die. Thus, in response to the same infection, vNKT cells appear to augment a robust proinflammatory response, whereas the iNKT cells dampen this response, possibly by regulating vNKT cells...
  35. pmc Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, WA 98104, United States
    Vaccine 29:9563-72. 2011
    ....
  36. pmc A synthetic adjuvant to enhance and expand immune responses to influenza vaccines
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, Washington, United States of America
    PLoS ONE 5:e13677. 2010
    ..These results suggest that synthetic TLR4 adjuvants can enhance the magnitude and quality of protective immunity induced by influenza vaccines...
  37. doi request reprint Rapid Quantitative Serological Test for Detection of Infection with Mycobacterium leprae, the Causative Agent of Leprosy
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, Washington, USA
    J Clin Microbiol 52:613-9. 2014
    ..Taken together, these data indicate that the NDO-LID/Smart Reader system can assist in the diagnosis and monitoring of MB leprosy and can detect a significant number of earlier-stage infections. ..
  38. pmc Adjuvants for Leishmania vaccines: from models to clinical application
    Vanitha S Raman
    Pre clinical Biology, Infectious Disease Research Institute, Seattle, WA, USA
    Front Immunol 3:144. 2012
    ....
  39. doi request reprint Use of defined TLR ligands as adjuvants within human vaccines
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA, USA
    Immunol Rev 239:178-96. 2011
    ....
  40. pmc During Trypanosoma cruzi infection CD1d-restricted NK T cells limit parasitemia and augment the antibody response to a glycophosphoinositol-modified surface protein
    Malcolm S Duthie
    Department of Pediatrics, Chiba University, Chiba, Japan
    Infect Immun 70:36-48. 2002
    ..cruzi infection the quality of an individual's NK T-cell response can affect the level of parasitemia and parasite tissue burden, the intensity of the chronic inflammatory responses, and possibly the outcome of Chagas' disease...